Vancomycin dosage in overweight and obese children.

Area of Science:

• Pediatric pharmacology
• Infectious disease management
• Clinical pharmacokinetics

Background:

• Vancomycin is a critical antibiotic for treating serious Gram-positive infections.
• Optimizing vancomycin dosing is crucial for efficacy and minimizing toxicity, especially in diverse patient populations.
• Overweight and obese pediatric patients present unique pharmacokinetic challenges that may affect drug distribution and clearance.

Purpose of the Study:

• To evaluate vancomycin dosages and therapeutic concentration attainment in overweight and obese children compared to normal-weight children.
• To identify factors influencing the achievement of target vancomycin trough concentrations (5-15 μg/mL).

Main Methods:

• Retrospective analysis of pediatric patients (2-17 years) receiving intravenous vancomycin.
• Stratification of patients into normal-weight and overweight/obese groups.
• Multivariate logistic regression to assess factors associated with achieving therapeutic vancomycin concentrations.

Main Results:

• Initial vancomycin doses (in mg) differed significantly between normal-weight and overweight/obese groups, but not when adjusted for weight (mg/kg).
• Every-eight-hour dosing regimens were associated with increased odds of achieving therapeutic vancomycin concentrations.
• Obese children had decreased odds of achieving therapeutic vancomycin concentrations compared to non-obese children.

Conclusions:

• Standard vancomycin dosing (mg/kg) did not differ significantly between normal-weight and overweight/obese children.
• Every-eight-hour dosing is more likely to achieve target vancomycin levels.
• Obesity is independently associated with a lower likelihood of achieving therapeutic vancomycin trough concentrations, suggesting potential need for weight-adjusted or individualized dosing strategies in this population.